All News Scandion Oncology A/S

Equities

SCOL

DK0061031895

Market Closed - Nasdaq Stockholm Other stock markets 11:29:57 2024-04-24 am EDT			5-day change	1st Jan Change
1.39 ^SEK	-3.81%		-44.40%	-65.21%

Mar. 21	Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival	CI
Mar. 07	Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scandion Oncology – Notice convening the Annual General Meeting	Apr. 19	AQ
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival	Mar. 21	AQ
Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival	Mar. 21	CI
Scandion Oncology - Annual Report 2023	Mar. 15	AQ
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial	Mar. 07	AQ
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial	Mar. 07	CI
Scandion Oncology Q4 2023 - Striving towards randomised controlled data	Mar. 01	AQ
Transcript : Scandion Oncology A/S, Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Scandion Oncology – Q4 & yearend report 2023	Feb. 28	AQ
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Scandion Oncology A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Invitation to Scandion Oncology webcast and conference call February 28, 2024	Feb. 22	AQ
Transcript : Scandion Oncology A/S - Special Call	Feb. 05
Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial	Jan. 31	AQ
Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial	Jan. 31	CI
Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101	Jan. 05	AQ
Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101	Jan. 05	CI
CORIST part 3 topline data are expected in the second half of January 2024	Dec. 21	AQ
Scandion Oncology Announces Presenting Topline Data in the Ongoing Corist Part 3 Study	Dec. 21	CI
Scandion Oncology identifies potentially effective treatment of gastric cancer	Dec. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Scandion Oncology A/S

Equities

SCOL

DK0061031895

All News

Filters